DK0696456T3 - Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme - Google Patents

Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme

Info

Publication number
DK0696456T3
DK0696456T3 DK95107299T DK95107299T DK0696456T3 DK 0696456 T3 DK0696456 T3 DK 0696456T3 DK 95107299 T DK95107299 T DK 95107299T DK 95107299 T DK95107299 T DK 95107299T DK 0696456 T3 DK0696456 T3 DK 0696456T3
Authority
DK
Denmark
Prior art keywords
necrosis
tumors
combination
inflammatory diseases
agents
Prior art date
Application number
DK95107299T
Other languages
Danish (da)
English (en)
Inventor
Klaus Dr Bosslet
Joerg Dr Czech
Dieter Dr Hoffmann
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0696456T3 publication Critical patent/DK0696456T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DK95107299T 1994-05-20 1995-05-13 Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme DK0696456T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4417865A DE4417865A1 (de) 1994-05-20 1994-05-20 Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Publications (1)

Publication Number Publication Date
DK0696456T3 true DK0696456T3 (da) 2001-06-25

Family

ID=6518684

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95107299T DK0696456T3 (da) 1994-05-20 1995-05-13 Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme

Country Status (14)

Country Link
US (1) US5710134A (fr)
EP (1) EP0696456B1 (fr)
JP (1) JP4576005B2 (fr)
KR (1) KR100386492B1 (fr)
AT (1) ATE199645T1 (fr)
AU (1) AU2015195A (fr)
CA (1) CA2149818C (fr)
DE (2) DE4417865A1 (fr)
DK (1) DK0696456T3 (fr)
ES (1) ES2154693T3 (fr)
GR (1) GR3035593T3 (fr)
NZ (1) NZ272150A (fr)
PT (1) PT696456E (fr)
ZA (1) ZA954099B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
ES2257756T3 (es) * 1996-03-12 2006-08-01 Sanofi-Aventis Deutschland Gmbh Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
EP2311490A3 (fr) 1998-07-13 2011-05-04 Board of Regents, The University of Texas System L'utilisation d'anticorps vis-à-vis des aminophospholipides pour le traitement du cancer
US10973397B2 (en) 1999-03-01 2021-04-13 West View Research, Llc Computerized information collection and processing apparatus
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
AU777620B2 (en) * 1999-04-09 2004-10-21 Jessie L.S. Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
EP1259548A1 (fr) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Anticorps specifique au domaine ed-b de la fibronectine, conjugues contenant cet anticorps, et utilisation pour la detection et le traitement de l'angiogenese
HUP0300935A3 (en) * 2000-09-07 2005-09-28 Schering Ag Receptor in the edb fibronectin domain
US20040247597A1 (en) * 2001-06-20 2004-12-09 Peter Carmeliet Method of treating atherosclerosis and other inflammatory diseases
WO2003014326A2 (fr) * 2001-08-10 2003-02-20 Imclone Systems Incorporated Isolation et mobilisation de cellules souches exprimant vegfr-1
CA2491310C (fr) 2002-07-15 2015-10-06 Board Of Regents, The University Of Texas System Compositions comprenant des derives de la duramycine impermeants vis-a-vis des parois cellulaires
CN102258503B (zh) 2004-01-22 2019-08-16 迈阿密大学 局部辅酶q10制剂及其使用方法
EP1722762A2 (fr) * 2004-03-02 2006-11-22 Massachusetts Institute of Technology Systeme d'administration de medicaments par nanocellules
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
JP4636020B2 (ja) * 2004-05-26 2011-02-23 株式会社ニコン 波長変換光学系、レーザ光源、露光装置、マスク検査装置、及び高分子結晶の加工装置
WO2006055809A2 (fr) * 2004-11-18 2006-05-26 Imclone Systems Incorporated Anticorps contre le recepteur 1 du facteur de croissance endotheliale vasculaire
US20090110633A1 (en) * 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2008147445A2 (fr) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Utilisation de l'acide 5,6-diméthylxanthénone-4-acétique en tant qu'agent antimicrobien
CA2705152C (fr) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Compositions d'anticorps anti-vegf et procedes correspondants
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) * 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4874780A (en) * 1987-03-11 1989-10-17 Norsk Hydro A.S. Anticancer compounds
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
AU1768692A (en) * 1991-03-27 1992-11-02 Lankenau Medical Research Center Method of administering drugs through modification of epithelial tight junctions
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
PT696456E (pt) 2001-07-31
CA2149818C (fr) 2010-03-23
NZ272150A (en) 1997-04-24
KR950031106A (ko) 1995-12-18
ZA954099B (en) 1996-01-19
ES2154693T3 (es) 2001-04-16
EP0696456A2 (fr) 1996-02-14
EP0696456B1 (fr) 2001-03-14
DE59509088D1 (de) 2001-04-19
GR3035593T3 (en) 2001-06-29
DE4417865A1 (de) 1995-11-23
KR100386492B1 (ko) 2003-08-14
AU2015195A (en) 1995-11-30
ATE199645T1 (de) 2001-03-15
US5710134A (en) 1998-01-20
JP4576005B2 (ja) 2010-11-04
JPH07316074A (ja) 1995-12-05
CA2149818A1 (fr) 1995-11-21
EP0696456A3 (fr) 1998-10-28

Similar Documents

Publication Publication Date Title
DK0696456T3 (da) Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
ES2192839T3 (es) Timosina beta 4 oxidada.
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
IL157821A0 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
ES2191192T3 (es) Tienopirimidinas.
BR9811099A (pt) Inibidores de urocinase
DK0902789T3 (da) Androstenderivater
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
NO994431L (no) Ny formulering
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
IT1318547B1 (it) Impiego dell'aloe-emodin nel trattamento di patologie neoplastiche diorigine neuroectodermica.
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
DE69328205D1 (de) Rektale Flunisolid-Zubereitung zur Behandlung entzündlicher Darmerkrankungen
DK1007047T3 (da) Anvendelse af mizolastin til fremstilling af et lægemiddel beregnet til inflammationsbehandling